Lineage-survival oncogenes are activated by somatic DNA alterations in cancers arising from the cell lineages in which these genes play a role in normal development 1,2 . Here we show that a peak of genomic amplification on chromosome 3q26.33 found in squamous cell carcinomas (SCCs) of the lung and esophagus contains the transcription factor gene SOX2, which is mutated in hereditary human esophageal malformations 3 , is necessary for normal esophageal squamous development 4 , promotes differentiation and proliferation of basal tracheal cells 5 and cooperates in induction of pluripotent stem cells [6] [7] [8] . SOX2 expression is required for proliferation and anchorage-independent growth of lung and esophageal cell lines, as shown by RNA interference experiments. Furthermore, ectopic expression of SOX2 here cooperated with FOXE1 or FGFR2 to transform immortalized tracheobronchial epithelial cells. SOX2-driven tumors show expression of markers of both squamous differentiation and pluripotency. These characteristics identify SOX2 as a lineage-survival oncogene in lung and esophageal SCC.
To identify genomic aberrations in lung and esophageal SCCs, we determined copy number for 40 esophageal SCC DNA samples (29 primary tumors and 11 cell lines) and 47 primary lung SCC DNA samples using 250K StyI Affymetrix SNP arrays. Data were analyzed using GISTIC (Genomic Identification of Significant Targets in Cancer) 1, 9 , which scores the significance of recurrent gains or losses and identifies peak regions likely to contain the driver gene(s).
For lung SCC, the most significant amplification peak is located on chromosome segment 3q26. 33 , with the next most significant peaks encompassing the tyrosine kinase genes EGFR on 7p11.2 and FGFR1 on 8p12 ( Fig. 1a , Table 1 and Supplementary Table 1 ). In esophageal SCC, the most significant amplification peak spans the cyclin gene CCND1 on 11q13.2; additional amplifications are found at EGFR, at FGFR1, at chromosome segment 3q26.33 and on 8q24. 21 near MYC and POU5F1B (Fig. 1b, Table 1 and Supplementary  Table 1 ). We also identified recurrent focal deletions, including deletions of CDKN2A and CDKN2B on 9p21.3 ( Supplementary Table 1 and Supplementary Fig. 1a ).
Chromosome segment 3q26.33 was amplified in 11 of the 47 (23%) lung and 6 of the 40 (15%) esophageal SCCs analyzed, as defined by SNP array-derived copy number of 3.6 or greater; this generally provides a substantial underestimate due to high tumor ploidy, normal DNA admixture or signal saturation at high copy numbers. As 5 of the 6 esophageal SCCs with the amplification were cell lines, we performed fluorescence in situ hybridization (FISH) on tissue microarrays (TMA) from 63 independent primary esophageal SCC samples and noted amplifications in 7 of 63 cases, confirming the presence of recurrent amplifications in primary tumors (data not shown).
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas The peaks on chromosome segment 3q26.33 occur within a previously defined focus of amplification within 3q26-3q28 in SCCs 10, 11 containing candidate oncogenes, including TP63 (ref. 12) , PIK3CA 13 and DCUN1D1 (ref. 14) . In our lung SCC analysis, the peak contained four genes (SOX2, ATP11B, DCUN1D1 and MCCC1) ( Fig. 1c and Table 1 ). In esophageal SCC, the 3q amplification peak includes only one annotated gene, SOX2 ( Fig. 1d and Table 1 ). Even for those samples with the highest copy number at PIK3CA and TP63, SOX2 was amplified to higher levels in the majority of these samples ( Supplementary Fig. 1b ). Although these results argue that SOX2 is a target of amplification, the absence of other genes from a GISTIC peak does not exclude an oncogenic role for genes other than SOX2, nor does it exclude polygenic contributions. Indeed, one lung SCC sample did harbor higher amplification at DCUN1D-ATP11B than at SOX2 (Supplementary Fig. 1b) , and one lung SCC sample also showed amplification at 183.03-183.27 Mb on chromosome 3, syntenic to the region containing lincRNA-Sox2, a noncoding RNA identified as a target of Sox2 in mouse embryonic stem (ES) cells 15 .
To evaluate the impact of 3q26.33 amplification on SOX2 expression, we measured SOX2 mRNA levels by quantitative RT-PCR in 27 lung SCCs for which matched SNP array data and RNA were available. Cases with SOX2 amplification had higher mRNA expression (P = 0.001; Supplementary Fig. 2a,b ). We noted several cases without 3q26.33 amplification that also had high SOX2 mRNA expression, suggesting that mechanisms other than amplification also can induce SOX2 overexpression. For esophageal SCC, we also documented the correlation of amplification and expression using immunohistochemistry and FISH on matched TMAs (Supplementary Fig. 2c ).
We next evaluated the essentiality of genes within and near the amplification peak at 3q26.33 for SCC cell lines bearing the amplification. We performed an arrayed RNA interference (RNAi) screen targeting SOX2, ten neighboring genes, two additional candidates (PIK3CA and TP63) and control short hairpin RNAs (shRNA) specific for GFP and LacZ (Supplementary Table 2 ). Three to ten independent shRNAs per gene were tested and analyzed after introduction into four SCC cell lines (esophageal lines TE10 and TT and lung lines NCI-H520 and HCC95) that harbor 3q26.33 amplification and two control lung adenocarcinoma cell lines that lack 3q26.33 amplification (NCI-H1437 and NCI-H1355).
Each shRNA construct was evaluated for its differential impact on proliferation, comparing its effect on the four amplified SCC lines to the two control cell lines. Expression of several independent shRNAs targeting SOX2 reduced proliferation of the SCC cell lines compared to their effects in controls ( Fig. 2a) . Analysis with the RNAi gene enrichment ranking (RIGER) 16, 17 algorithm showed that suppression of SOX2 has the largest differential antiproliferative effects on the 3q26.33 amplified SCC cell lines among all genes tested ( Fig. 2a) . Because prior work had implicated DCUN1D1 as a potential 14 , we further validated the results of shRNA constructs targeting this gene and consistently noted less effect for knockdown of this gene relative to SOX2 (Supplementary Note and Supplementary Fig. 3a,b) . These observations suggest that SOX2 is an essential gene in SCCs with 3q26.33 amplifications.
To determine in more detail the requirement for amplified SOX2, we examined cell lines expressing SOX2-directed or control shRNAs (shSOX2a, shSOX2b and shGFP) ( Fig. 2b) . Suppression of SOX2 with either of two SOX2-directed shRNA constructs reduced proliferation in the four 3q26.33-amplified lines but not in controls without appreciable SOX2 expression ( Fig. 2c) . We next evaluated anchorage-independent growth. TE10, TT and NCI-H1355 cells were not tested because these cell lines fail to form colonies in soft agar. shRNA targeting SOX2 decreased colony formation in SOX2-amplified HCC95 and NCI-H520 cells compared to NCI-H1437 cells (Fig. 2d) . Further results suggest that the reduction in anchorage independence upon SOX2 knockdown exceeds that which would be caused by the induced reduction in proliferation and that SOX2 is essential for some tumor cells with lower-level copy gain at 3q26.33 (Supplementary Note and Supplementary Fig. 3c,d) .
To confirm that the effects of SOX2 shRNA are attributable to SOX2 suppression, we tested whether we could rescue the effects of suppression of SOX2 with ectopic wild-type SOX2 or SOX2 R74P, a loss-offunction DNA-binding domain mutant identified in an individual with congenital tracheoesophageal fistula 3 . We introduced wild-type and mutant SOX2 into HCC95 cells and subsequently introduced shSOX2b, which targets the SOX2 3´ UTR. Expression of wild-type SOX2 restored anchorage-independent growth, whereas both SOX2 R74P and GFP control did not ( Fig. 2e) . These observations demonstrate a clear requirement for SOX2 and argue against the possibility that the effects of shSOX2b on HCC95 cells are due to off-target toxicity.
We next examined the ability of SOX2 to transform immortalized tracheobronchial epithelial (AALE) cells 18 . As SOX2 alone was not transforming, we searched lung SCC expression data 19 for genes whose expression correlated with SOX2 expression ( Supplementary Table 3 ) with P values marked as above. Immunoblots for SOX2 and vinculin are shown. l e t t e r s as candidates for cooperative transformation. The most highly correlated gene was FOXE1, encoding a forkhead transcription factor gene on chromosome 9q22.33, which is also the locus harboring the most significantly associated germ-line risk allele for thyroid cancer (followed by the NKX2-1 locus) 20 . FOXE1 is expressed in the epithelium of the developing esophagus 21 , and congenital mutations in FOXE1 cause cleft palate and hypothyroidism 22 . Another highly correlated gene, the receptor tyrosine kinase gene FGFR2, was of particular interest given that activating mutations are observed in lung SCC 23 .
Although neither SOX2 nor FOXE1 ectopic expression alone was transforming, their coexpression induced anchorage-independent growth (Fig. 3a) . However, we were unable to demonstrate a stable physical interaction between SOX2 and FOXE1 with coimmunoprecipitation (data not shown). Also, the suppression of FOXE1 with RNAi did not reduce proliferation of SCC cell lines, and the FOXE1 protein was not appreciably expressed in all SOX2-dependent SCC lines (data not shown), suggesting that FOXE1 is not broadly required for SOX2 function.
To investigate potential cooperation between SOX2 and FGFR2, we similarly generated stable AALE lines by ectopic expression of SOX2, the IIIb or IIIc splice variants of wild-type FGFR2, or both genes. Neither SOX2 nor FGFR2 expression alone could transform AALE cells, but the combination of SOX2 with the FGFR2 IIIb isoform found in epithelial cancers promoted anchorage-independent growth (Fig. 3b) . In contrast, expression of the 'mesenchymal' isoform IIIc failed to transform these cells with SOX2 (Fig. 3b) . These results demonstrate that SOX2 can be transforming with multiple cooperating genes. Further work will be required to elaborate the genes that can act with SOX2 in tumorigenesis and the subtypes of tumors in which these genes are active.
In prior reports, we and others have identified the developmental transcription factor gene NKX2-1 (also called TITF1) as an amplified lineage-survival oncogene in lung adenocarcinoma 1, [24] [25] [26] . Within the primitive foregut of mice, there is reciprocal expression of Nkx2-1 and Sox2 in compartments that form the trachea and esophagus, respectively 4 . Experimentally, Nkx2-1 −/− mice form hypoplastic lungs that stem from an undivided foregut with Sox2 + /p63 + squamous epithelium 4 . By contrast, mice that express a hypomorphic Sox2 allele develop tracheoesophageal fistulae and form an esophagus with a ciliated Nkx2-1 + /p63mucosa 4 . Hypothesizing that SOX2 may similarly represent a lineage-survival oncogene, we compared the expression and amplification patterns of these two genes between lung adenocarcinomas and SCCs. We found SOX2 amplifications to be enriched in the lung SCC tumor population, whereas NKX2-1 amplification was enriched in lung adenocarcinoma (Supplementary Fig. 4a,b) ; this is consistent with a previous study of NKX2-1 (ref. 24 ) and with a report that the copy number of lung adenocarcinoma and SCC are distinguished by SCCspecific amplification of chromosome 3q at 180-200 Mb 27 . SNP array analysis from multiple adenocarcinoma lineages including esophageal adenocarcinomas failed to identify significant SOX2 amplification (R. Beroukhim, C.H. Mermel, D. Porter, G. Wei, S. Raychaudhuri, J. Donovan et al., unpublished data). Furthermore, mRNA expression data 19, 28 show that SOX2 mRNA levels are significantly higher in the lung SCC population compared to adenocarcinomas, whereas NKX2-1 expression is significantly higher in adenocarcinomas ( Supplementary  Fig. 4c,d) . The complementary roles of SOX2 and NKX2-1 in distinct cancer lineages thus parallel their actions in development.
In addition to its role in the development and maintenance of esophageal and tracheal tissues, SOX2 is also a key factor in pluripotency and one of the factors that allows reprogramming of mature cells to pluripotent stem cells [6] [7] [8] . Although the lineage-restricted nature of SOX2 amplifications in lung and esophageal SCC argues that it functions as a lineage-survival oncogene, we sought to determine how the role of SOX2 as a pluripotency factor could contribute to its oncogenic activity. Expression analysis across other tumor lineages has identified signatures of ES cells in subsets of tumors; these tumors tend to be poorly differentiated and to be associated with decreased survival 29 . Querying lung SCC expression data with these signatures, we noted ES-like signatures and expression of targets of the core ES transcription factors in tumors with higher SOX2 expression ( Fig. 4a) . However, individuals presenting with lung SCC tumors that showed the ES signature had better survival than those without the signature (P value for Kaplan-Meier plot = 0.03; data not shown), and we did not identify significant association of SOX2 amplification or expression with clinical grade.
In contrast, expression of SOX2 correlates with markers of squamous differentiation in lung SCCs. TP63 and KRT6A, which encode the squamous markers p63 and cytokeratin 6A, respectively, were among the 50 transcripts most correlated with SOX2 expression in lung SCCs ( Supplementary Table 3 ). When SOX2 was ectopically expressed in the lung adenocarcinoma line NCI-H2009, both TP63 and KRT6A were induced (Fig. 4b) , demonstrating actions of SOX2 that promote squamous identity rather than de-differentiation to a pluripotent state, and thus consistent with a role for this gene as a lineage-survival oncogene.
This is the first report to show that SOX2 is an amplified oncogene in lung or esophageal SCC. SOX2 has critical roles in foregut development, where it regulates initial dorsal-ventral patterning 4 , shapes epithelial-mesenchymal interactions and is required for proper differentiation both of the squamous esophagus 4 and of multiple respiratory cell types 5 . SOX2 retains essential functions in the adult foregut, where it is expressed in the proliferative basal esophagus 30 and in the putative tracheal and airway stem cells 5, 31 , where SOX2 is necessary for proliferation and response to injury 5 . SOX2-driven SCCs likely co-opt multiple functions regulated by SOX2 in the normal foregut and may activate additional pathways controlled by SOX2 in early pluripotent cells. Given the complexity of these functions and the involvement of interactions of multiple cell types, further study of the oncogenic function of SOX2 will require engineered animal and organotypic tissue culture models. The elucidation of SOX2-dependent pathways in these models may identify new therapeutic vulnerabilities in SCC and uncover additional common pathways between cancer, normal development and the maintenance of pluripotency.
MeTHoDS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Accession codes. SNP array data are available via the Gene Expression Omnibus (GEO) accession GSE17958. diagnosis had their tumor's expression profile included in the analysis. To identify genes correlated with SOX2, we identified the ten lung SCCs with the highest SOX2 expression and ten with the lowest SOX2 expression. To identify correlated genes, differential expression was calculated using the same package in Bioconductor 36 . We used gene-set expression analysis 37 to assess whether the signatures that define ES cell identity are active and related to SOX2 expression level in lung SCC tumors. SOX2 mRNA expression was characterized as high and low in cases with expression 0.5 s.d. above or below the mean, respectively. The analysis utilized nine gene sets that were previously defined to be overexpressed in ES cells and performed as previously described 29 .
Real-time PCR assays. For expression analysis, RNA was extracted from cells using the Qiagen RNeasy kit and cDNA prepared with the Qiagen QuanTiTECT cDNA synthesis kit. All real-time PCRs were performed in triplicate with Power PCR SYBR Green Master Mix (Applied Biosystems) on a 7300 Real-Time PCR System (Applied Biosystems) with results normalized to GAPDH expression. Primers are listed in Supplementary Table 2. Immunohistochemistry. TMAs were stained with a polyclonal SOX2 antibody (Chemicon) at 1:5,000 dilution following Dako antigen retrieval 38 . After staining, we scanned the TMAs with the ZEISS MIRAX Scanner (Zeiss, Oberkochen, Germany) and then used the AxioVision Software to measure the gray scale value. Protein expression was quantified by the gray scale values of the epithelial cells and defined as a value from 0 (black) to 255 (white).
For statistical analysis, values were inverted so that higher expression (black) corresponded to higher numerical values.
Statistical analysis.
For comparisons of all continuous variables between experimental groups, Student's t tests were used. Effects of SOX2 RNAi on cellular proliferation was modeled by fitting the growth curve of each cell line to an exponential growth model using GraphPad Prism software. Modeled growth curves for each shSOX2-expressing cell line were compared to that for the appropriate shGFP-expressing cell line curve; F tests were used to determine P values. P values < 0.05 were considered significant; Bonferroni correction was performed for all experimental results in cell lines.
